Pharmafile Logo

Relistor

- PMLiVE

Minds + Assembly Launches Assembled Intelligence and Adds Stratevi to Expand Market Access and HEOR Solutions

New York, NY — 10.23.2025 — Minds + Assembly, a leading healthcare marketing firm, today announced the launch of Assembled Intelligence, an integrated communications and commercialization platform designed to unite...

BOLDSCIENCE

- PMLiVE

BMS, Takeda and Astex join AI training consortium

The initiative focuses on training AI models to aid in drug discovery and development

- PMLiVE

Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma

The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma

- PMLiVE

Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP

The enzyme replacement therapy is now the first treatment approved in the UK for this patient population

- PMLiVE

Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma

The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication

- PMLiVE

Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma

Around 800 people in the UK are diagnosed with late-stage disease every year

- PMLiVE

Takeda/Protagonist share positive phase 3 results for rusfertide in rare blood cancer

Up to 160,000 people in the US are affected by polycythaemia vera

- PMLiVE

Takeda and EU Innovative Health Initiative launch Crohn’s disease prevention study

Approximately three million people in Europe are affected by inflammatory bowel disease

- PMLiVE

Takeda’s mezagitamab shows promise in immune thrombocytopenia

The rare immunoglobulin-mediated autoimmune disease affects four in every 100,000 people annually

- PMLiVE

Takeda’s Fruzaqla approved by EC to treat metastatic colorectal cancer in adults

Approximately 538,000 new cases of colorectal cancer were diagnosed in Europe in 2022

- PMLiVE

Takeda shares long-term results for HyQvia in rare neurological disorder CIDP

The therapy is the first and only facilitated subcutaneous immunoglobulin treatment for CIDP

- PMLiVE

Takeda shares late-stage results for investigational soticlestat in rare epileptic disorders

Dravet syndrome and Lennox-Gastaut syndrome are drug-resistant to many anti-seizure medications

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links